PTC/SB/08s (08-03.)
Approved for use through 07/31/2006, ONE 0851-0031
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless of contains a valid OMB control number.

Remove

Application Number | Filing Date | Filing Date | Filing Date | Filing Market | Filing Date | Filing Market | Filing Market | Filing Market | Filing Market | Filing Date | Filing Market | Fil

Examiner Name

Attorney Docket Number HRCM P005USNP

Under the Paperwork Reduction Act of 1995, no pe

(Not for submission under 37 CFR 1.99)

				,				
				U.S.	PATENTS		Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Paten of cited Docum	tee or Applicant ent	Pages,Columns Relevant Passa Figures Appear	Lines where ges or Relevant
	1	5666821			Foster			
	2	4258075			Hendricks			
	3	6223542			Jones			
	4	5785581			Settles			
	5	4748817			Oura			
If you wis	h to a	d additional U.S. Paten					Add	
			U.S.P	ATENT APPLI	CATION PUBLIC	CATIONS	Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Paten of cited Docum	tee or Applicant ent	Pages,Columns Relevant Passa Figures Appear	Lines where, ges or Relevant
	1							
If you wis	h to a	d additional U.S. Publis	hed Ap	plication citation	n information ple	ase click the Ad	d button Add	1

FOREIGN PATENT DOCUMENTS

	Application Number		
	Filing Date		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Craig	
(Not for submission under 37 CFR 1.99)	Art Unit		
,,	Examiner Name		
	Attorney Docket Numb	er	HRCM.P005USNP

Pages, Columns, Lines

where Relevant

Name of Patentee or

Date Considered

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Applicant of cited Document	Passages or Relevant Figures Appear	Τs
	1							С
If you wish to add additional Foreign Patent Document citation information please click the Add button								
	NON-PATENT LITERATURE DOCUMENTS Remove							
		lastuda assas afilha a	other (in CADITA	LIET	TEDE) ille of	the estate (chan encoun	rinto) title of the item	

Kind Publication

Examiner Cite Foreign Document

Examiner Signature

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	Ţŝ
	1		

If you wish to add additional non-patent literature document citation information please click the Add button EXAMINER SIGNATURE

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO

Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sensi number of the patent document Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

	Application Number		
	Filing Date		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Craig	i
(Not for submission under 37 CFR 1.99)	Art Unit		
,	Examiner Name		
	Attorney Docket Numb	er	HRCM.P005USNP

CERTIFICATION STATEMENT

sace are of or the first and find the appropriate assessmental.
That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

OR

That no item of information contained in the information disclosure statement was cited in a communication from a
foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification
after making reasonable inquiry, no item of information contained in the information disclosure statement was known to
any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure
statement.

000	attacileu	Columbation	otatement.		

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

SIGNATU

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the
form of the signature.

· -		
Signature	Date (YYYY-MM-DD)	
Name/Print	Registration Number	

This collection of Information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 US.C. 122 and 37 CFR 1.14. This collection is estimated to site it hour to complete, including gathering, preparing and submitting the comparing of application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you proceed the process of the USPTO. The will vary depending upon the individual case. Any comments on the amount of time you proceed the process of the USPTO. The process of the USPTO. The process of the process of the process of the process of the USPTO. The USPTO

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is SU U.S. C. (2)(2)(2) (2) famishing of the information solicide is voluntary, and (3) the principal purpuses for which the information is used by the U.S. Patient and Trademan Kolline is to process another examines your submission related to a patient application or patient. If you do not furnish the requested process another examines your submission related to a patient application or patient. If you do not furnish the requested the process another examines your submission related to a patient application or patient. If you do not furnish the requested the process another examines your submission, which may related the process and/or examines your submission, which may related the process and/or examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disease records.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, cuting an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make indemninations a partial individuals.
 - 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1-14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.